Haemonetics Corporation
HAE
NYSE·Healthcare·Medical - Devices·Mkt cap $4.7B
$103.96
▼ -0.99%
P/E
32.69
Mkt Cap
$4.7B
52-Wk Range
$47.32–$109.57
52-Week Range
$47.32 - $109.57
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 90.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary automated collection and analysis technologies with high switching costs and regulatory barriers
- Integrated software platforms (NexLynk DMS, SafeTrace Tx, BloodTrack, TEG Manager) creating ecosystem lock-in across customer operations
- Decades of R&D expertise and FDA-cleared portfolio serving mission-critical blood management and hemostasis assessment applications
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Rising global demand for plasma-derived therapies and increased plasma donation center expansion
Value
Fairly valued vs Medical Devices peers
Momentum
Hot
+53.3% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HAE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $1.14 vs $1.08 consensus (+5.6% surprise). Revenue of $339.4M vs $327.9M expected (+3.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.6%
Revenue trend · last 8Q
—
—
+4%
-4%
-4%
-5%
-3%
+6%
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q1 27
$336.2M
$345.5M
$348.5M
$330.6M
$321.4M
$327.3M
$339.0M
$339.4M
Margins · last 8Q
Gross
59.8%
Operating
16.9%
Profit
9.7%
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: Bank of America · Aug 12, 2026
vs Industry
How HAE stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related